ASCO® 2026 Highlights: Presenter Vignettes
Videos
Day 1
Click one or more tumour names to filter results
Chinese University of Hong Kong
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Thomas Jefferson University Hospital
A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)–naive basal cell carcinoma of the head and neck.
University of Chicago Medicine
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
Washington University
Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.
Gustave-Roussy Cancer Campus
The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.
Day 2
Click one or more tumour names to filter results
BC Cancer
First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
MD Anderson Cancer Center
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC).
Day 3
Click one or more tumour names to filter results
Chinese University of Hong Kong
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Thomas Jefferson University Hospital
A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)–naive basal cell carcinoma of the head and neck.
University of Chicago Medicine
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
Washington University
Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.
Gustave-Roussy Cancer Campus
The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.